From OHC, Specialists in Cancer and Blood Disorders
December 20, 2019
A new clinical trial available at OHC is evaluating the use of the immunotherapy drug, durvalumab, for patients with inoperable, early stage non-small cell lung cancer (NSCLC).
The survival rate for lung cancer depends on which stage the cancer has reached, but overall the five-year survival rate is 18% according to the American Cancer Society. OHC doctors are evaluating the use of the immunotherapy drug, durvalumab, administered after the patient has received stereotactic body radiation therapy (SBRT) to determine if it improves the overall survival rate.
“The use of immunotherapy has demonstrated promising results in patients with Stage 3 non-small cell lung cancer,” said OHC’s Joseph Shaughnessy, MD, radiation oncologist, who is the principal investigator for this clinical trial. “Now we want to see if it is effective for patients with earlier stage cancers who aren’t eligible for surgery.”
Patients who meet guidelines will receive SBRT, and then will be chosen to receive durvalumab versus observation. Durvalumab helps the immune system recognize and destroy cancer cells. It has already been FDA-approved for stage 3 NSCLC, and this clinical trial at OHC is evaluating the effectiveness in earlier stages.
“If the results of this trial are promising, this new combination of SBRT and immunotherapy could become a life-saving option for these patients,” Dr. Shaughnessy added. “This is another example of why OHC participates in clinical trials – to give patients the best chance to beat their cancer.”
OHC is at the forefront of the latest treatments for cancer through its clinical trials program. For more information about lung cancer treatments, OHC clinical trials, or a second opinion, please visit ohcare.com or call 1-888-649-4800.Comments (0)